Invasive candidiasis: current clinical challenges and unmet needs in adult populations
暂无分享,去创建一个
Á. Soriano | P. Honore | P. Verweij | D. Gonçalves-Bradley | C. García-Vidal | P. Puerta-Alcalde | Anna Pagotto
[1] Fu Lee Wang,et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial , 2022, The Lancet.
[2] F. Barchiesi,et al. Antifungal Combinations against Candida Species: From Bench to Bedside , 2022, Journal of fungi.
[3] Fen Zhang,et al. The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly. , 2022, The Lancet. Microbe.
[4] M. Garg,et al. Clinical features, diagnosis and treatment outcome of fungal endocarditis: A systematic review of reported cases , 2021, Mycoses.
[5] Deepak Kumar,et al. Candida Pneumonia: An Innocent Bystander or a Silent Killer? , 2021, Medical Principles and Practice.
[6] C. Sprung,et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 , 2021, Intensive Care Medicine.
[7] P. Schlattmann,et al. Risk Factors for Invasive Candida Infection in Critically Ill Patients , 2021, Chest.
[8] I. Spriet,et al. Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients , 2021, Microorganisms.
[9] R. Attou,et al. T2MR can be used as a non-culture-based test together with biomarkers to improve detection of Candida in the bloodstream and reduce time delay in treating invasive candidiasis , 2021, Expert review of anti-infective therapy.
[10] Yong Jun Kwon,et al. Dynamics and Predictors of Mortality Due to Candidemia Caused by Different Candida Species: Comparison of Intensive Care Unit-Associated Candidemia (ICUAC) and Non-ICUAC , 2021, Journal of fungi.
[11] P. White,et al. Evaluation of the Performance of the Associates of Cape Cod STAT Assay for the Diagnosis of Invasive Fungal Disease in Critical-Care Patients with COVID-19 , 2021, Journal of clinical microbiology.
[12] P. Pappas,et al. Candidemia and Invasive Candidiasis. , 2021, Infectious disease clinics of North America.
[13] D. Andes,et al. Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions , 2021, Current opinion in infectious diseases.
[14] Á. Soriano,et al. Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies , 2021, Open forum infectious diseases.
[15] N. Safdar,et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis , 2021, PloS one.
[16] M. Cheng,et al. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta‐analysis , 2021, Mycoses.
[17] J. Timsit,et al. Performance of Repeated Measures of (1–3)-β-D-Glucan, Mannan Antigen, and Antimannan Antibodies for the Diagnosis of Invasive Candidiasis in ICU Patients: A Preplanned Ancillary Analysis of the EMPIRICUS Randomized Clinical Trial , 2021, Open forum infectious diseases.
[18] M. Zimmerman,et al. Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model , 2021, Antimicrobial Agents and Chemotherapy.
[19] T. Gabaldón,et al. Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium , 2020, Antibiotics.
[20] A. Pasqualotto,et al. Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids? , 2020, Journal of fungi.
[21] M. Netea,et al. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? , 2020, Journal of fungi.
[22] Guanghua Huang,et al. Candida auris: Epidemiology, biology, antifungal resistance, and virulence , 2020, PLoS pathogens.
[23] I. Martín-Loeches,et al. Invasive candidiasis in critical care: challenges and future directions , 2020, Intensive Care Medicine.
[24] Á. Soriano,et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] M. Ghannoum,et al. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections , 2020, Antibiotics.
[26] A. Chowdhary,et al. Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs , 2020, Antimicrobial Agents and Chemotherapy.
[27] B. Willinger,et al. Molecular Methods for the Diagnosis of Invasive Candidiasis , 2020, Journal of fungi.
[28] F. Chrétien,et al. Central nervous system candidiasis beyond neonates: Lessons from a nationwide study. , 2020, Medical mycology.
[29] A. Gómez-López. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[30] M. Arendrup,et al. Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Candida Causing Candidemia at Distant Geographical Areas , 2020, Frontiers in Cellular and Infection Microbiology.
[31] T. Khan,et al. The Economic Burden of Candidemia and Invasive Candidiasis: A Systematic Review. , 2020, Value in health regional issues.
[32] C. Lass‐Flörl,et al. Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time , 2020, Expert review of anti-infective therapy.
[33] A. L. Lima,et al. Prosthetic joint infection due to Candida species , 2020, Medicine.
[34] A. Christe,et al. Risk factors for candidemia: a prospective matched case-control study , 2020, Critical Care.
[35] M. Bassetti,et al. Changes in the relative prevalence of candidaemia due to non‐albicans Candida species in adult in‐patients: A systematic review, meta‐analysis and meta‐regression , 2020, Mycoses.
[36] Christina A. Cuomo,et al. Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses , 2020, mBio.
[37] G. Catano,et al. The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris , 2019, Antimicrobial Agents and Chemotherapy.
[38] W. Powderly,et al. Risk factors predicting Candida infective endocarditis in patients with candidemia. , 2019, Medical mycology.
[39] Rachel M. Kenney,et al. T2 Candida versus beta-D-glucan to facilitate antifungal discontinuation in the intensive care unit. , 2019, Diagnostic microbiology and infectious disease.
[40] W. Powderly,et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. , 2019, The Journal of antimicrobial chemotherapy.
[41] J. Bohlius,et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[42] Xu-guang Guo,et al. Pooled analysis of T2 Candida for rapid diagnosis of candidiasis , 2019, BMC Infectious Diseases.
[43] A. Flannery,et al. Need for expanded Candida Score for empiric antifungal use in medically critically ill patients? , 2019, Critical Care.
[44] M. Ghannoum,et al. Resistance of Candida to azoles and echinocandins worldwide. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[45] M. Antonelli,et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project , 2019, Critical Care.
[46] Shuzhen Wei,et al. Diagnostic accuracy of Candida albicans germ tube antibody for invasive candidiasis: systematic review and meta-analysis. , 2019, Diagnostic microbiology and infectious disease.
[47] S. Mertens,et al. SANRA—a scale for the quality assessment of narrative review articles , 2019, Research integrity and peer review.
[48] Ronald N. Jones,et al. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 , 2019, Open forum infectious diseases.
[49] J. Pemán,et al. Candidemia from urinary tract source: the challenge of candiduria , 2018, Hospital practice.
[50] J. Sobel,et al. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. , 2018, Clinical Infectious Diseases.
[51] D. Perlin,et al. Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata , 2018, Journal of fungi.
[52] P. Ljungman,et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. , 2018, The Journal of antimicrobial chemotherapy.
[53] J. Sohn,et al. Prosthetic Joint Infections Caused by Candida Species: A Systematic Review and a Case Series , 2018, Mycopathologia.
[54] D. Seidel,et al. Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship , 2018, European Journal of Clinical Microbiology & Infectious Diseases.
[55] Viviane Maria de Carvalho Hessel Dias,et al. Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study , 2018, Medical mycology.
[56] A. Caliendo,et al. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] B. Kullberg,et al. Invasive Candidiasis. , 2019, The New England journal of medicine.
[58] J. Schrenzel,et al. Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. , 2018, The Journal of infection.
[59] D. Kontoyiannis,et al. Advances in the diagnosis and treatment of fungal infections of the CNS , 2018, The Lancet Neurology.
[60] C. Castillo,et al. Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis—The ESCAPE Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[61] C. Clancy,et al. Diagnosing Invasive Candidiasis , 2018, Journal of Clinical Microbiology.
[62] Miguel C. Teixeira,et al. Candida Biofilms: Threats, Challenges, and Promising Strategies , 2018, Front. Med..
[63] E. Mylonakis,et al. Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial , 2018, Journal of Clinical Microbiology.
[64] A. Booth,et al. A comparison of results of empirical studies of supplementary search techniques and recommendations in review methodology handbooks: a methodological review , 2017, Systematic Reviews.
[65] K. Hanson,et al. Candida auris: an Emerging Fungal Pathogen , 2017, Journal of Clinical Microbiology.
[66] R. Manuel,et al. Candida auris: a Review of the Literature , 2017, Clinical Microbiology Reviews.
[67] Felix Bongomin,et al. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.
[68] B. Dervaux,et al. Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial , 2017, Intensive Care Medicine.
[69] M. Bassetti,et al. Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis , 2017, Expert review of anti-infective therapy.
[70] Yee-Chun Chen,et al. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species , 2017, BMC Infectious Diseases.
[71] J. Pemán,et al. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] A. Chowdhary,et al. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally , 2017, PLoS pathogens.
[73] F. Dromer,et al. The risk and clinical outcome of candidemia depending on underlying malignancy , 2017, Intensive Care Medicine.
[74] C. Clancy,et al. Emergence of Candida auris: An International Call to Arms. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[75] Christina A. Cuomo,et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[76] C. Steiner,et al. Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002–2012 , 2017, Emerging infectious diseases.
[77] E. Bouza,et al. The current treatment landscape: the need for antifungal stewardship programmes. , 2016, The Journal of antimicrobial chemotherapy.
[78] A. Cortegiani,et al. Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why? , 2016, Critical Care.
[79] B. Souweine,et al. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial. , 2016, JAMA.
[80] S. Luque,et al. Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp. , 2016, International journal of antimicrobial agents.
[81] M. Castanheira,et al. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). , 2016, Diagnostic microbiology and infectious disease.
[82] J. Vincent,et al. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy , 2016, Critical Care.
[83] J. Rello,et al. Invasive candidiasis: from mycobiome to infection, therapy, and prevention , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[84] S. Park,et al. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment , 2016, PloS one.
[85] J. Sobel,et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[86] J. Pemán,et al. Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[87] S. Bailly,et al. Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study , 2016, Annals of Intensive Care.
[88] M. Hernandez,et al. CARD9-Dependent Neutrophil Recruitment Protects against Fungal Invasion of the Central Nervous System , 2015, PLoS pathogens.
[89] M. Castanheira,et al. Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis. , 2015, Medical mycology.
[90] M. Antonelli,et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality , 2015, Intensive Care Medicine.
[91] E. Bouza,et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[92] D. Denning,et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. , 2015, The Lancet. Infectious diseases.
[93] D. Stippel,et al. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole , 2015, European Journal of Clinical Microbiology & Infectious Diseases.
[94] H. Fan,et al. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs , 2014, European Journal of Clinical Microbiology & Infectious Diseases.
[95] A. Shorr,et al. Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study , 2014, Critical Care.
[96] A. Mitchell,et al. Fungal biofilms, drug resistance, and recurrent infection. , 2014, Cold Spring Harbor perspectives in medicine.
[97] F. Queiroz-Telles,et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period , 2014, Intensive Care Medicine.
[98] D. Pittet,et al. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later , 2014, Intensive Care Medicine.
[99] T. Calandra,et al. Polymorphisms in Tumor Necrosis Factor-&agr; Increase Susceptibility to Intra-Abdominal Candida Infection in High-Risk Surgical ICU Patients* , 2014, Critical care medicine.
[100] P. Escribano,et al. Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. , 2014, Medical mycology.
[101] C. Neoh,et al. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives. , 2014, International journal of antimicrobial agents.
[102] F. Queiroz-Telles,et al. Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin , 2014, Antimicrobial Agents and Chemotherapy.
[103] Á. Soriano,et al. Usefulness of time-to-positivity in aerobic and anaerobic vials to predict the presence of Candida glabrata in patients with candidaemia. , 2013, The Journal of antimicrobial chemotherapy.
[104] A. Shorr,et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts , 2013, Intensive Care Medicine.
[105] J. Desimone,et al. Candida cerebral abscesses: a case report and review of the literature. , 2013, Medical mycology.
[106] C. Charbonneau,et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species , 2013, European Journal of Clinical Microbiology & Infectious Diseases.
[107] T. Calandra,et al. Invasive candidiasis as a cause of sepsis in the critically ill patient , 2013, Virulence.
[108] C. Clancy,et al. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[109] F. Pea. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. , 2013, Current clinical pharmacology.
[110] Duncan W. Wilson,et al. Candida albicans pathogenicity mechanisms , 2013, Virulence.
[111] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[112] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[113] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[114] B. Moriyama,et al. Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[115] C. Castro,et al. Value of β-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions , 2012, Intensive Care Medicine.
[116] Joshua A. Doherty,et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[117] D. Horn,et al. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. , 2012, Diagnostic microbiology and infectious disease.
[118] J. Sobel,et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[119] M. Wolff,et al. Diagnosis, management and outcome of Candida endocarditis. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[120] R. Rajendran,et al. Fungal Biofilm Resistance , 2012, International journal of microbiology.
[121] C. Imbert,et al. Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials? , 2012, The Journal of antimicrobial chemotherapy.
[122] J. Chhablani. Fungal endophthalmitis , 2011, Expert review of anti-infective therapy.
[123] M. Antonelli,et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index , 2011, Critical care.
[124] A. Shorr,et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans : a multivariate analysis of factors associated with improved outcome , 2016 .
[125] J. Sobel,et al. Ocular manifestations of candidemia. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[126] L. Baddour,et al. Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis , 2011, Mycoses.
[127] M. Ghannoum,et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. , 2011, Diagnostic microbiology and infectious disease.
[128] K. Sepkowitz,et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .
[129] J. Perfect,et al. Early treatment of candidemia in adults: a review. , 2011, Medical mycology.
[130] T. Calandra,et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia , 2010, Critical care.
[131] L. Leibovici,et al. PCR Diagnosis of Invasive Candidiasis: Systematic Review and Meta-Analysis , 2010, Journal of Clinical Microbiology.
[132] M. Joannidis,et al. Human Tissue Distribution of Voriconazole , 2010, Antimicrobial Agents and Chemotherapy.
[133] Ronald N. Jones,et al. Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) , 2010, Journal of Clinical Microbiology.
[134] G. Velmahos,et al. Candida infection and colonization among trauma patients , 2010, Virulence.
[135] J. Wingard,et al. Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B: A Review and Meta-Analysis , 2010, Medicine.
[136] A. Zaas,et al. Breakthrough Invasive Candidiasis in Patients on Micafungin , 2010, Journal of Clinical Microbiology.
[137] Thomas J Walsh,et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[138] Jordi Rello,et al. International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.
[139] Russell E. Lewis,et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001‐2007) , 2009, Cancer.
[140] V. Fowler,et al. Candida infective endocarditis , 2008, European Journal of Clinical Microbiology & Infectious Diseases.
[141] R. Betts,et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[142] R. Betts,et al. Anidulafungin versus fluconazole for invasive candidiasis. , 2007, The New England journal of medicine.
[143] D. Pittet,et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.
[144] B. Alexander,et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting , 2007, European Journal of Clinical Microbiology & Infectious Diseases.
[145] J. Korevaar,et al. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing , 2006, Intensive Care Medicine.
[146] J. Zimmerman,et al. Acute Physiology and Chronic Health Evaluation (APACHE) IV: Hospital mortality assessment for today’s critically ill patients* , 2006, Critical care medicine.
[147] J. Garnacho-Montero,et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization* , 2006, Critical care medicine.
[148] A. Webster,et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. , 2016, The Cochrane database of systematic reviews.
[149] C. Viscoli,et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial , 2005, The Lancet.
[150] Peter Bauer,et al. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission , 2005, Intensive Care Medicine.
[151] J. le Gall,et al. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 1: Objectives, methods and cohort description , 2005, Intensive Care Medicine.
[152] Hsin-Pai Chen,et al. Clinical characteristics, treatment and prognostic factors of candidal meningitis in a teaching hospital in Taiwan , 2004, Scandinavian journal of infectious diseases.
[153] D. Pittet,et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[154] N. Matsuda,et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration , 2003, Intensive Care Medicine.
[155] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[156] D. Kontoyiannis,et al. Breakthrough Candidemia in Patients with Cancer Differs from De Novo Candidemia in Host Factors and Candida Species But Not Intensity , 2002, Infection Control & Hospital Epidemiology.
[157] A. Colombo,et al. Risk Factors for Breakthrough Candidemia , 2002, European Journal of Clinical Microbiology and Infectious Diseases.
[158] E. Anaissie,et al. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[159] G. O’Toole,et al. Microbial Biofilms: from Ecology to Molecular Genetics , 2000, Microbiology and Molecular Biology Reviews.
[160] J. Romero-Vivas,et al. The central nervous system and infection by Candida species. , 2000, Diagnostic microbiology and infectious disease.
[161] M. Barza. Editorial Response: Treatment Options for Candidal Endophthalmitis , 1998 .
[162] D. Sullivan,et al. Candida dubliniensis: Characteristics and Identification , 1998, Journal of Clinical Microbiology.
[163] C. Quereda,et al. Candidal meningitis in HIV-infected patients: analysis of 14 cases. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[164] A. Cassone,et al. Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies. , 1996, Blood.
[165] V. Yu,et al. Meningitis caused by Candida species: an emerging problem in neurosurgical patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[166] R. Auckenthaler,et al. Candida Colonization and Subsequent Infections in Critically III Surgical Patients , 1994, Annals of surgery.
[167] W. Knaus,et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.
[168] W. S. Head,et al. Ocular uptake of fluconazole following oral administration. , 1990, Archives of ophthalmology.
[169] J. Perfect,et al. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis , 1987, Antimicrobial Agents and Chemotherapy.
[170] W. Knaus,et al. APACHE II: a severity of disease classification system. , 1985 .
[171] J. Perfect,et al. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. , 1984, Reviews of infectious diseases.
[172] B. Salehi,et al. Novel Therapies for Biofilm-Based Candida spp. Infections. , 2019, Advances in experimental medicine and biology.
[173] T. Calandra,et al. Changes in the epidemiological landscape of invasive candidiasis , 2018, The Journal of antimicrobial chemotherapy.
[174] P. Pappas,et al. Invasive Candidiasis. , 2016, Infectious disease clinics of North America.
[175] S. Bailly,et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. - Trends over 10 years. , 2016, The Journal of infection.
[176] B. Kullberg,et al. Invasive Candidiasis. , 2015, The New England journal of medicine.
[177] P. Hamal,et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[178] M. Angelopoulou,et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[179] R. Wenzel,et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. , 2014, International journal of antimicrobial agents.
[180] D. Horn,et al. Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry , 2013, European Journal of Clinical Microbiology & Infectious Diseases.
[181] H. Einsele,et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. , 2012, Medical mycology.
[182] L. Pagano,et al. Design and Methods , 2022 .
[183] M E Ellis,et al. Fungal endocarditis: evidence in the world literature, 1965-1995. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[184] J. Sobel,et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[185] T. C. White,et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.